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Summary HDAC inhibitors (HDACI) are now emerging as
one of the most promising new classes of drugs for the
treatment of select forms of non-Hodgkin’s lymphoma (NHL).
They are particularly active in T-cell lymphomas, possibly
hodgkin’s lymphoma and indolent B cell lymphomas. Present-
ly, two of these agents, vorinostat and romidepsin, have been
approved in the US for the treatment of relapsed and refractory
cutaneous T cell lymphomas (CTCL). Initially, these agents
were developed with the idea that they affected transcriptional
activation and thus gene expression, by modulating chromatin
condensation and decondensation. It is now clear that their
effects go beyond chromatin and by affecting the acetylation
status of histones and other intra-cellular proteins, they modify
gene expression and cellular function via multiple pathways.
Gene expression profiles and functional genetic analysis has led
to further understanding of the various molecular pathways that
are affected by these agents including cell cycle regulation,
pathways of cellular proliferation, apoptosis and angiogenesis
all important in lymphomagenesis. There is also increasing data
to support the effects of these agents on T cell receptor and
immune function which may explain the high level of activity
of these agents in T cell lymphomas and hodgkin’s lymphoma.
There is ample evidence of epigenetic dysregulation in
lymphomas which may underlie the mechanisms of action of
these agents but how these agents work is still not clear. Current
HDAC inhibitors can be divided into at least four classes based
on their chemical structure. At present several of these HDAC
inhibitors are in clinical trials both as single agents and in
combination with chemotherapy or other biological agents.
They are easy to administer and are generally well tolerated
withminimal side effects. Different dosing levels and schedules
and the use of isospecific HDAC inhibitors are some of the
strategies that are being employed to increase the therapeutic
effect of these agents in the treatment of lymphomas. There
may also be class differences that translate into specific activity
against different lymphoma. HDAC inhibitors will likely be
incorporated into combinations of targeted therapies both in the
upfront and relapsed setting for lymphomas.
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Introduction
Epigenetic modifications are encompassed by one of three
distinct biological processes: (1) acetylation and deacetyla-
tion of histones catalyzed by histone acetyltransferases
(HAT) and histone deacetylases (HDAC); (2) genome
methylation; and (3) small silencing RNA (siRNA). The
first two of these pathways have emerged in recent years as
a promising new strategy for the treatment of many
different hematologic malignancies, with HDAC inhibitors
(HDACI) now emerging as one of the most promising new
classes of drugs for the treatment of select forms of non-
Hodgkin’s lymphoma (NHL). Presently, two HDACI,
vorinostat and romidepsin, have been approved in the US
for the treatment of relapsed and refractory cutaneous T cell
lymphomas (CTCL) [1, 2]. By affecting the acetylation
status of histones and other intra-cellular proteins, drugs
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inhibiting HDAC can modify gene expression and cellular
function [3]. Initially, these agents were developed with
the idea that they modulated transcriptional activation and
thus gene expression, by modulating chromatin condensa-
tion and decondensation. More recently, it has been
recognized and now generally accepted, that the effects
of HDACI go well beyond chromatin, and includes a
plethora of effects on the post-translational modification of
many intracellular proteins. Though the fundamental
mechanisms of HDACI inhibitor action are discussed in
other chapters, it is worth highlighting particular concepts
that will be germane to understanding these agents in B-
and T-cell lymphoma.
DNA is packaged around a core of eight histone proteins
(a pair of histones 2A, 2B, 3 and 4) into discrete units
called nucleosomes [4]. Acetylation of the ε-amino moie-
ties on the lysine tails of the histone leads to an open, or
transcriptionally active decondensed state of chromatin
which is accessible to transcription factors, and thus
allows for transcription of various genes. The condensed
or closed chromatin state, catalyzed by the deaceytlation
of the lysine tails, prevents access of the transcription
factors to the structure of the DNA leading to transcrip-
tional silencing. These reactions are catalyzed by two
major classes of enzymes referred to as HATs and HDAC.
HDAC inhibitors block these HDAC enzymes, and thus
maintain the chromatin in an acetylated and transcript-
tionally active state. Histones themselves also undergo
many different types of post-translational modifications
though most is probably known about acetylation as
described above. Emerging insights into other post-
translational modifications like methylation suggest these
reactions may play equally important roles in governing
transcription, and may be an equally valid target for drug
development.
To date over 18 different HDACs have been identified,
being grouped into four classes based on their homology to
yeast proteins, as shown in Table 1. In brief, these include:
(1) Class I enzymes consisting of HDAC1, HDAC2,
HDAC3, HDAC8, (2) class II enzymes consisting of
HDAC4, HDAC5, HDAC7, HDAC9, HDAC6, HDAC10;
and (3) class IV enzymes consisting of HDAC11. These
HDACs all require a Zn molecule in their active site and are
inhibited by what are often referred to as ‘pan’ HDAC
inhibitors [5]. The unique class III HDAC, also known as
sirutins (Sirutin 1-7), are homologous to yeast Sir 2 protein,
require NAD+ as a coenzyme for their activity and are not
affected by the pan HDAC inhibitors [6].
The biological importance of histone deacetylases has
been demonstrated in mouse knockout models. Genetic
deletions of class I enzymes [7] are lethal in the embryonic
and perinatal stages of development, whereas class II [8]
knockouts produce viable progeny, though they do exhibit
significant developmental abnormalities. The pharmacolog-
ic inhibition of HDAC leads to several downstream effects
in tumor cell lines which can be categorized as follows [9]:
(1) cell cycle arrest in G1-S phase; (2) induction of
apoptosis mediated by effects on pro- and antiapoptotic
mechanisms of cell death; (3) inhibition of angiogenesis;
(4) effects on the endoplasmic stress response; (5) effects
on the activation or inactivation of tumor suppressor genes
or oncogenes involved in growth control and cell death.
This confirms that the pharmacologic inhibition of histone
deacetylases can lead to pleiotropic effects on signaling
pathways that affect proliferation, differentiation, angiogen-
esis and cell survival [10–12]. Uniquely, the Class III
HDAC enzymes (also referred to as the sirutins), together
with NAD+, lead to the production of the deacetylated
peptides, nicotinamide, and ADP ribose. Nicotinamide is a
negative regulator of this reaction and thus an inhibitor of
class III HDACs. Sirutins couple the processes of lysine
acetylation and deacetylation to the metabolic NAD/NADH+
pathway and have been shown to be important in the
regulation of transcription, recombination, cell division, cell
cycling, microtubule assembly, and cellular responses to stress
and DNA damaging agents [6].
Dysregulation of Epigenetic pathways
in lymphoproliferative malignancies
While there is still much to learn regarding the basic
biological implications of modifying HATs and HDAC
enzymes, it is clear that they control many essential aspects
of normal and abnormal cell behavior. Inhibition of HDAC
is associated with a pleiotropic set of consequences, many
of which are likely to vary as a function of the HDAC
inhibitor, the cellular context, and perhaps even the
concentration or dose of a specific agent. New concepts
that are emerging regarding the importance of this biology
on carcinogenesis have focused on the balance of HAT and
HDAC activity [13]. For example, the tight control of the
acetylation or deacetylation of key proteins, similar to our
understanding of phosphorylation and control of the
kinome, can have profound effects on the activation or
inactivation of important transcription factors like E2F, p53,
NF-KB, HIF alpha, estrogen receptor, signaling pathway
Table 1 Classification of histone deacetyalse inhibitors
Class Targeted enzymes Required co factor
I HDAC 1,2,3,8 Zn2+
II HDAC 4,5,7,9, 6, 10 Zn2+
III SIRTUINS 1-7 NAD+
IV HDAC 11 Zn2+
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proteins like STAT3, chaperone proteins like hsp-90, DNA
repair enzyme like Ku70 and structural proteins like alpha
tubulin. The wide range of proteins affected by the many
different HDAC enzymes, coupled with the many new
drugs now targeting this biology, suggests we may only be
at the beginning in figuring out how to manipulate the
‘acetylome’ in a fashion that will both prevent and treat
diverse forms of cancer through epigenetic modulation
[14].
The promising activity of HDAC inhibitors in certain
types of lymphomas has prompted investigators to look at
the expression of HATs, HDACs and other epigenetic
markers in different types of lymphomas to pinpoint a
mechanisms of action and a rationale for the observed anti
lymphoma effect. The results have only shown that the
clinical effect is at best empirical at the moment. Some of
this data is discussed below.
CTCL has been the disease with the highest clinical
response rates with HDAC inhibitors prompting studies of
HDAC expression and other epigenetic markers in CTCL to
look into the molecular basis of this responsiveness.
Marquard et al. [15] have evaluated the expression of
HDAC1, HDAC2, HDAC6 and acetylated H4 by immu-
nohistochemistry in 73 samples of CTCL obtained from
patients with variable clinical courses ranging from indolent
to aggressive and correlated their findings with survival in
this cohort of patients. Their results have shown clear
differences in the expression of certain markers within
certain subgroups of the disease but have not provided any
insight into the therapeutic benefit seen with epigenetic
therapy. When comparing aggressive versus indolent cases,
no difference was found in the expression of HDAC1, and
HDAC6 but the expression of HDAC2 and acetylated H4
was found to be higher in aggressive disease compared to
indolent (HDAC2—55.5%—aggressive CTCL vs 15%
indolent, acetylated H4—22% aggressive vs 8% indolent).
Survival correlated with the over expression of HDAC-6
(p=0.04, hazard ratio 0.39) independent of CTCL subtype.
Dysregulation of other epigenetic pathways particularly
promoter site hypermethylation has been identified in many
lymphoid malignancies including CTCL. Van Doorn et al.
[16, 17] compared genome-wide DNA methylation screen-
ing of CTCL samples with benign skin disorders and
carried out methylation profiling using DNA isolated from
patient specimens including those with transformed disease.
In the initial screens, widespread promoter hypermethyla-
tion suggestive of epigenetic instability was demonstrated
in malignant T-cells in CTCL. At least 35 CpG islands were
hypermethylated in tumor stage CTCL samples including
that of the putative tumor suppressor gene BCL7a (B-cell
CLL/Lymphoma 7) in 48% of samples, PTPRG gene
(protein tyrosine phosphatase receptor gamma) in 27% of
samples and THBS4 gene (thrombospondin 4) in 52% of
the samples. These genes were also hypermethylated in the
CTCL cell line Myla but not in the control samples.
Treatment of this cell line with a hypomethylating agent 5-
aza-2- azacitidine resulted in re-expression of these genes
as detected by quantitative PCR. Bcl-7 is of particular
interest because a higher frequency of hypermethylation of
BCL-7 (and inactivation) was observed in samples from
patients with more aggressive disease (64%) compared to
indolent CTCL (14%). BCL-7, which is located on
chromosome 12q 24.31 has been cloned as part of the
chromosomal translocations seen in Burkitt’s lymphoma
and is at a site of frequent breakpoints in lymphoma [18].
While the exact cellular function of BCL7a is unknown at
present, its expression has been shown to be diminished in
mycosis fungoides and PTCL compared with lymphoblastic
lymphoma indicating possible contribution to lymphoid
malignancies arising from mature T cells. PTGR is a
member of the tyrosine phosphatase gene superfamily, and
is commonly silenced across many types of human
malignancies [19], while THBS4 encodes for an extracel-
lular calcium binding protein involved in proliferation,
adhesion and migration and has been reported to be
hypermethylated in other cancers besides CTCL [20]. Other
well known tumor suppressor genes shown to have
promotor hypermethylation in 21 CTCL samples as
compared to samples from normal skin in volunteers
included p73 (48%), p16 (33%), CHFR (19%), p15 (10%)
and TMS1 (10%). The CpG islands of the DNA repair gene
MGMT gene were hypermethylated in all tested CTCL
samples as a well as the three control samples. In general,
these hypermethylated genes can be grouped into the
following functional categories: cell cycle dysregulation
(p15, p16, p73), defective DNA repair (MGMT), apoptosis
dysregulation (TMS1, p73) and chromosomal instability
(CHFR). p73 is responsible for activation induced death of
T-cells and its silencing leads to accumulation of T cells in
tissues, an important step in the pathogenesis of CTCL [21–
24]. Hypermethylation of p73 has also been described in
nodal B-cell and NK-cell lymphomas [24]. Promoter
hypermethylation of p16 has been demonstrated in many
lymphoid malignancies, including CD30+ T-cell NHL.
CHFR encodes for a protein regulating the mitotic
checkpoint pathway that regulates the transition to meta-
phase and its silencing may contribute to chromosomal
instability [25–27]. Hypermethylation of p16 and MLH1
gene have also been detected in patch/plaque MF [26–28]
indicating their contribution to pathogenesis in early stages
of CTCL.
Epigenetic dysregulation has also been studied in other
types of lymphoma and there is evidence that HDAC
expression can be variable depending on the type and
aggressiveness of the disease. Using western blots and
immunohistochemistry, Gloghini et al. [29] have studied
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the expression of several class I and II HDACS in a diverse
panel of lymphoma cell lines, primary samples of benign
reactive lymph nodes (n=5), as well as biopsy samples of
various lymphomas (DLBCL n=171, T cell n=5, Hodgkin
lymphoma n=22, and other B cell lymphomas n=152). All
14 lymphoma cell lines uniformly expressed the class 1
HDAC enzymes (1,2,3,8) but there was significant vari-
ability in the expression of class II enzymes. In particular
HDAC 6 expression was high in mantle cell lymphoma,
DLBCL and T-cell derived lymphoma cell lines but low in
multiple myeloma, Hodgkin lymphoma and anaplastic large
cell lymphoma cell lines. The class IV HDAC 11 was
expressed in all cell lines. Subsequently, the authors
compared the expression of HDACs in normal reactive
nodes to the pattern of expression seen in primary
lymphoma samples to look for any differences that may
contribute to lymphomagenesis. Within reactive lymph
nodes there was almost uniform expression of class I
HDACs in all cellular compartments. But consistent with
the cell line data, HDAC2 enzymes were differentially
expressed in cellular compartments with HDAC10 present
in all cellular compartments and HDAC6 expression restricted
to plasma cells. The relative expression of HDACs has been
studied across many subtypes of lymphoma within primary
samples from lymphoma patients. Class I HDACs 1,2,3,
8 were expressed in all NHL and HL cases. Class II HDAC
expression was more variable, with class 10 being present in
all cases of NHL and classical HL, while HDAC6 being
present in B cell lymphomas with plasmacytoid/ plasmablastic
differentiation. Interestingly, only two of 52 cases of DLBCL
expressed HDAC6 which was absent in all 22 cases of HL.
The class IV HDAC 11 was expressed in all lymphoma cell
lines, all samples of NHL and in none of the four HL cases that
were tested. The importance of this variability becomes
apparent in the following set of observations. Villagra et al.
[30] have shown that over expression of HDAC11 inhibits
interleukin 10 expression and induces inflammatory antigen
presenting cells that are able to prime naïve T-cells and
restore the responsiveness of tolerant CD4+ cells. Disruption
of HDAC11 in APCs leads to the upregulation of expression
of the gene encoding for IL-10 leading to impairment of T-
cell responses. Hence, aberrant expression of HDACs in the
microenvoirnment of lymphoma may also be important for
immunomodulation and antitumor immune responses [31]
and may lead to opportunities for therapeutic interventions.
This data clearly points to the variability in the
expression of HDACs within different tissue and tumor
types even though these differences may not be fully
defined yet. These observations remain important as we
refine our efforts to design even more selective HDAC
inhibitors, and sort out the best disease contexts within
which to explore their activity. Similar to the proteasome
inhibitors, it remains unlikely that developing the best
isoselective HDAC inhibitor will be the optimal strategy to
move these agents forward, but rather understanding the
down-stream consequences of inhibiting specific HDAC
enzymes coupled with our understanding of how addicted
any given malignancy is to that particular biology, may
prove the optimal rationale for matching the drug to the
disease. It is also likely that pan-HDAC inhibition may
afford coverage of a broader spectrum of biology that may
be associated with even greater benefit in comparison to
more isoselective inhibitors.
Recently, the Class II HDAC6 has gained a lot of
attention. As mentioned above, HDAC6 is one of the most
variable HDAC enzymes. It is known to affect the
acetylation status of several proteins including alpha—
tubulin, and is important in the regulation of microtubule
stability and function. In addition, it may serve as a
molecular chaperone, and plays a role in regulating the
aggresome, a proteosome independent pathway that elim-
inates misfolded protein [32] shown to be important in
some cancers. Interestingly, mice knocked out for HDAC6
show hyperacetylated tubulin in most tissues but remain
viable and fertile with normal lymphoid development [33]
This linkage between inhibition of an HDAC and the
proteasome pathway has now raised a strong mechanistic
rational for the combination of these agents in the clinical
setting, much of which is centered around the unfolded or
misfolded protein response. Misfolded proteins are thought
to be degraded either via the ubiquitin-proteosome pathway,
and possibly through the aggresome. Misfolded proteins
destined for the aggresome are thought to be transported
along microtubules via the activity of motor proteins like
dyne and adapters proteins like HDAC6, to the microtubule
organizing center (MTOC), which in turn transports these
proteins to the lysosome for degradation as part of the
HDAC-6—aggresome pathway. Pharmacologic inhibition
of HDAC-6 results in hyperacetylation of tubulin and
disruption of the aggresome mediated pathway resulting in
apoptosis, which may explain the mechanistic basis for
their synergy with proteosome inhibitors [29, 34]. It should
be pointed out, that there is no evidence that inhibiting one
HDAC enzyme over another is associated with improved
activity, nor is there evidence that more selective HDAC
inhibitors will be associated with an improved adverse
effects profile.
Molecular pharmacology of histone deacetylase
inhibitors
Inhibition of HDACs is known to be associated with
myriad effects on tumor cells, which has made it exceed-
ingly difficult to establish a true mechanistic pathway of
how these agents work in lymphoma, and T-cell lympho-
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mas in particular. Biochemically, HDAC inhibitors main-
tain histones and other intracellular proteins in an acetylated
state. These biochemical modifications are known to be
associated with a variety of downstream biological effects
including the activation or inactivation of transcription,
influences on cell cycle regulation and apoptosis, and many
pro-differentiating effects. Gene expression profiling (GEP)
of cells that have been treated with HDAC inhibitors has
shown that up to 22% of the genes in the genome can be
modulated with these agents within as early as 4 h post-
treatment [35, 36]. Efforts to identify a discrete mechanistic
role for any specific HDAC inhibitor based on the alteration
of a specific gene expression profile remains elusive. The
major effects of HDAC inhibition on cancer cells are
grouped as follows:
Effects of HDAC inhibitors on cell cycle control
and proliferation
Among the many pleiotropic effects that HDAC inhibitors
have on cells, perhaps the most is known about their effects
on cell cycle regulation and control. It is well established
that HDAC inhibitors block cell proliferation and cause
apoptosis in cell lines derived from both hematologic and
solid tumor malignancies by causing cell cycle arrest in G1
or G2/M mainly by altering the expression of proteins
(cyclins, cyclin dependent kinase inhibitors,) involved in
growth control [37]. HDAC inhibitors repress the expres-
sion of cyclin D [38, 39] and cyclin A which reduces the
activity of CDK4 and CDK2 leading to cell cycle arrest in
G1. HDAC inhibitors also cause up-regulation of p21, p27
and p16 leading to inhibition of cell cycle progression after
binding to and inactivating CDK4 and CDK2 [40, 41]. The
consistently observed increase in p21 expression is consid-
ered to be one of the most important mechanisms leading to
HDAC inhibitor mediated G1/S arrest [42]. As clinical
efficacy of HDAC inhibitors gets established in the
treatment of lymphomas, the field is now poised to study
specific HDAC inhibitors for their effects in specific
subtypes of lymphoma in order to identify discrete differ-
ences seen in the epigenitc modifications produced by the
different agents. Vorinostat has been shown to cause
acetylation of histones H2B, H3, and H4 associated with
increased expression of p21 resulting in G2 arrest and
apoptosis in CTCL and HL cell lines [43]. Peart et al. [35]
have used GEP and small interfering RNA (siRNA)
experiments to look at the effect of two recently approved
HDAC inhibitors, vorinostat and romidepsin on gene
expression in T-cell lymphoblastic cell lines (CEM, Jurkat).
Cell lines exposed to either of these agents resulted in
changes noted in a highly overlapping set of up to 22% of
the genes in the cells within a 16 h culture period. Cyclin D
was consistently down regulated by vorinostat, whereas the
expression of several other cyclins, including G1, G2, E1,
E2, F and B2, as well as their inhibitors CDK2m CDK2N2,
and CDK2AP1), were affected by both HDAC inhibitors.
Ellis et al. [44] studies the patterns of gene expression in
patients with CTCL pre- and post-treatment with panobino-
stat. They demonstrated a consistent downregulation of
Cyclin D1 which was confirmed by RT-PCR. Other
mechanisms of action that lead to cell cycle arrest have
been demonstrated in cell lines where vorinostat, trichosta-
tin A, and MS-27-275 have all been shown to result in
transcriptional downregulation of enzymes important in
nucleotide synthesis. These effects were seen primarily in
CTP synthetase and thymidylate synthetase, and were
associated with tumor cell death by inducing cell cycle
arrest in S phase [45]. Butyrate and TSA, two aliphatic acid
HDAC inhibitors, have been shown to induce GADD45
alpha and beta subunits (a stress induced gene downstream
of p53) in colon cancer cell lines which may contribute to
the G2/M arrest [46].
There is increasing evidence that drugs targeting HDAC
can affect several pathways that are important in cell
proliferation and differentiation of lymphoid cells, includ-
ing the b-TGF pathway, the JAK-STAT pathway, myc and
Bcl-6 [35]. Peart et al. [35] have demonstrated that
following exposure to HDAC inhibitors, there was a rapid
increase in the expression of a number of antiproliferative
genes including TOB1, TOB2, BTG2, that all belong to a
family of genes important in neuronal differentiation.
Members of this family are p53 inducible, are activated in
conditions of genotypic stress and can impair G1-S
progression. The oncogene c-myc, which is known to be
dysregulated in several lymphomas, in particular in
Burkett’s lymphoma through the t (8–14), was shown to
be downregulated after exposure of the malignant cells to
vorinostat and romidepsin [35]. At the same time, three
members of the same myc family (i.e. MXII, MAD, and
MLX) were up regulated. Typically, MAD competes with
MAX and inhibits the transcriptional activity of MYC
leading to the hypothesis that treatment with HDAC
inhibitors can produce a loss of MYC driven transactivation
and cell proliferation. Another important gene that is
upregulated by both vorinostat and romidepsin is the TIEG
(TGF Beta inducible early response genes), which is
upstream of the type B-TGF pathway and is involved in
mediating responses that control cellular differentiation and
apoptosis via the TGF-B pathway [47]. Similarly the ID
((inhibitor of differentiation) genes, ID2 and ID3 that
induce lymphocyte growth arrest and apoptosis are also
rapidly upregulated by HDAC inhibitors [48] and may
result in cell death. Bcl-6 is a gene that encodes for a
protein that acts as a sequence-specific repressor of
transcription, and has been shown to modulate the
transcription of STAT-dependent Interleukin 4 (IL-4)
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responses of B cells. BCL-6 is frequently translocated and
hypermutated in diffuse large B cell lymphoma (DLCL),
and serves as a transcriptional repressor inhibiting p53 and
other genes involved in the control of lymphocyte activa-
tion, differentiation and apoptosis. Acetylation of Bcl-6 by
HDAC inhibitors abrogates this effect allowing the genes
repressed by Bcl-6 to be activated [49, 50]. Panobinostat,
another hydroxamic acid HDAC inhibitor, has been shown
to suppress proliferation genes including NR2F2, Cyclin D
and TM4SF18 [44] as demonstrated by gene expression in
tissue obtained from skin samples of the patients CTCL
both before and after treatment. The direct effect of HDAC
inhibitors on non-histone proteins can also affect the
growth and differentiation of cells. These proteins are
broadly grouped as transcriptional coregulators (e.g. RB,
MSL-3, DEK, PGC-1α), DNA binding transcriptional
factors (e.g. BCL-6, p53, c-Myc, E2F, GATA, Ying Yang,
NF-κB, CREB, IRF), signaling mediators (e.g. STAT-3,
IRS-1), chaperone proteins (e.g. HSP90), steroid receptors
(e.g. androgen, estrogen, and glucocorticoid), and DNA
repair enzymes (e.g. WRN, KU70, and FEN1) [35, 51–57].
The STAT family of transcription factors is particularly
important because of their important role in lymphoma-
genesis. In particular STAT 3 is found to be constitutively
activated in CTCL, HL and several other lymphomas [58].
After treatment with vorinostat, p-STAT-3, localized to the
cytoplasm from the nucleus in patient samples with CTCL
who had responded [59]. Since nuclear translocation is
essential to the function of transcription factors, this shift
maybe indicative of inactivation of STAT 3 thus correlating
with the antilymphoma effect of vorinostat.
Effects of HDACI on survival pathways
Many lines of preclinical data have established a direct
correlation between apoptotic tumor cell death and thera-
peutic efficacy of HDAC inhibitors. Gene expression
profiling has revealed that treatment of cells with HDAC
inhibitors results in expression of proteins that favor a pro-
apoptotic response and suppresses anti-apoptotic mecha-
nisms [60, 61]. HDAC inhibitors-induce death of tumor
cells through the induction of both the internal and external
pathways of apoptosis, as well as through non-apoptotic
mechanisms like autophagy [62]. The specific evidence
regarding details of these effects are described as follows:
Extrinsic apoptotic pathway The extrinsic apoptotic path-
way designed to induce apoptosis in response to extra
cellular stimuli is induced by engagement of the DISC
(death induced signaling complex) via cell surface receptors
and their interaction with ligands that ultimately lead to
caspase 8 activation [63, 64] and apoptotic death via the
final common pathway. Like all other activities in the cell,
this is controlled by several sets of opposing protein
pathways that determine the fate of the cell and are
modulated by HDAC inhibitors. Specifically, HDAC
inhibitors have been shown to increase the expression of
genes that encode for death receptors and their ligands such
as Fas and the Apo 2L/TRAIL receptors, DR4 and DR5,
and to downregulate c-FLIP, c1AP2, and X1AP that inhibit
the death receptor pathway [65]. The use of neutralizing
antibodies and siRNAs that target TRAIL, Fas, or over
expression of cFLIP can protect tumors form HDAC
inhibitor induced apoptosis, confirming the mechanistic
role of the extrinsic apoptotic pathway in HDAC inhibitor
induced cell death.
Intrinsic apoptotic pathway The intrinsic apoptotic path-
way gets activated from internal cellular stimuli that result
in increased mitochondrial permeability and release of
cytochrome c, Smac, and Omi into the cytosol via the
mitochondrial voltage-dependent anion channel (VDAC)
and are coupled with the induction of Apaf-1 (apoptosis
pathway activating factor that leads to caspase 9 and 3
activation and activation of the final common pathway of
apoptosis. The tendency towards intrinsic apoptosis is
tightly managed by a litany of pro- and anti-apoptotic
proteins ( Bcl-2, Bcl-xL, NOXA), as well as the BH3 only
proteins like Bid, Bik and Bim. Treatment of cells with
HDAC inhibitors results in perturbation of this balance
shifting the cell towards or away from the induction of
apoptosis [66, 67]. Interestingly, the over expression of
Bcl2 and siRNA-mediated knockdown experiments of Bad,
Bim, and Noxa reduces the apoptotic effects of HDAC
inhibitors. It is now becoming increasingly important that
any potential differences in the biological activity between
specific HDAC inhibitors, or even classes of HDAC
inhibitors (say for example aliphatic acids vs hydroxamic
acids vs natural product macrolides like romidepsin) be
established. Vorinostat and romidepsin are two HDAC
inhibitors that have been approved for clinical uses and are
the most extensively studied in this regard. They differ in
their chemical structure as well as their potency regarding
in-vitro cytotoxicity assays and their respective EC50 for
the different HDAC enzymes. Both agents have been
shown to induce caspase dependent apoptosis in lymphoma
cell lines derived from Eu-myc mouse models and
xenograft mouse models of mice bearing Eu-myc lympho-
ma tumors show increased survival and absence of tumor at
autopsy following treatment with vorinostat or romidepsin
[35]. However, these agents differ with respect to their
effects on specific apoptotic and antiapoptotic proteins that
may lead them to have differing therapeutic implications.
Knockout mice models of specific proteins in the apoptotic
pathways have been used to delineate the specific mecha-
nisms of apoptosis for each of these agents [68, 69].
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Vorinostat induces apoptosis in a p53 independent manner
but was unable to kill cells that over expressed Bcl-2 (as is
seen in many human B cell lymphomas) and Bcl-XL in this
model system. Interestingly, over expression of Bcl-2
conferred resistance to apoptosis mediated by other HDAC
inhibitors as well, including LAQ824, LBH589, valproic
acid and MS-275 where as romidepsin induced apoptosis in
cells that over expressed Bcl-2 but not those over-
expressing Bcl-xL, suggesting that a unique difference
between these agents. Both Bcl-2 and Bcl-xL are anita-
poptotic proteins that function by interacting with Bax and
Bak, and thus work collaboratively to prevent mitochon-
drial membrane depolarization and induction of apoptosis.
Bcl-xL may be may be more critical in different stages of
B-cell ontogeny (i.e. more important in immature B cells
for example) and ten times more effective than Bcl-2 in
inhibiting apoptosis mediated by chemotherapeutic agents
like doxorubicin and etoposide, whereas Bcl-2 may be
more important in more mature B-cells (i.e. follicular
lymphoma for example) [70, 71]. This and other reports
have highlighted other potentially important differences
between vorinostat and romidepsin, including: (a) the
cleavage and activation of the BH3—only protein Bid
occurs in a caspase independent manner following treat-
ment with vorinostat but is dependent on caspase activition
in response to romidepsin; (b) the multidrug resistant gene
P-glycoprotein can inhibit apoptosis induced by romidepsin
whereas it has no effect on vorinostat. Another hydroxamic
acid panobinostat has been shown to affect genes involved
in apoptosis including Septin 10, TEF and SORBS2 [44].
In addition to these modulatory effects on the proteins
governing apoptosis, the antiapoptotic effects of HDAC
inhibitor can also be mediated by several indirect mecha-
nisms that lead to cell death by apoptosis. One such
important pathway involves the generation of reactive
oxygen species (ROS) [72] that lead to increased mito-
chondrial permeability and consequent activation of the
apoptotic pathway. HDAC inhibitors have been shown to
induce ROS and treatment of cells with ROS scavenging
molecules like N-acetyl cysteine and thioredoxin can lead
to protection of the cell against HDACI mediated apoptosis.
Post-translational modification of proteins through the
maintenance of an acetylated state of proteins like Bid,
thioredoxin, and regulators of ROS may be an additional
mechanism contributing to apoptosis [73].
Autophagy HDAC inhibitors also induce non-apoptotic cell
death possibly by autophagy. Blockade of caspase-mediated
apoptosis bya pan-apoptosis inhibitors like z-vad still
induces to cell death, suggesting that other non-apoptotic
can be invoked following HDAC inhibition, which most
reports now believe is likely to be mediated by autophagy,
although the precise mechanism is not yet known [74].
By understanding the specific effects of the different
HDAC inhibitors on apoptosis and cell cycle control for
example, it will be possible to conceptualize rational drug:
drug combinations that will take advantage of the underly-
ing molecular pharmacology to develop likely synergistic
platforms in a very cell context focused manner.
Antiangiogenic effects
HDAC inhibitors have been shown to have anti-angiogenic
effects that appear to be mediated by various mechanisms
including upregulation of angiogenesis inhibitors like
thrombospondin, Von-Hippel Landau factor, as well as
down regulation of factors that promote vasculogenesis
including vascular endothelial growth factor (VEGF) and
HIF-a (hypoxia induced protein). HDAC inhibitors also
downregulate the expression of survivin, an anti-apoptotic
protein in endothelial cells, thereby inhibiting the growth of
vascular endothelium [75, 76] and interfering with vasculo-
genesis. Tumor samples from patients treated with vorino-
stat have shown clear evidence of decreased vascularity
consistent with this observation [59]. A number of genes
that are known to affect angiogenesis including the
proangiogenic ANGPT1 and guynalate cyclase 1A3
(GUCY1A3) and were also found to be downregulated
after treatment with panobinostat [44].
Clinical pharmacology of histone deacetylase inhibitors
HDACI are a chemically diverse group of naturally
occurring and synthetic molecules found to inhibit the
activity of HDACs in a wide range of concentrations from
low nM to high mM [13, 77] as listed in Table 2. Presently,
there are at least 18 different HDAC inhibitors being
evaluated in preclinical and early clinical trials that target
the Zn dependent (i.e. Class 1 and 2) HDACs, including
two agents already approved for the treatment of CTCL in
the U.S., namely vorinostat and romidepsin. Table 3 lists all
current HDAC inhibitors undergoing clinical evaluations.
Most HDAC inhibitors have a short plasma half life
(vorinostat- 2 h [78], romidepsin- hrs [79], MGCD0103-
9 h [80] and undergo hepatic metabolism either via the
CYP450 system (romidepsin) [81] or the glucoronidation
system (vorinostat) [82]. The metabolites are excreted
through the biliary and fecal routes. Romidepsin is highly
protein bound in plasma (92% to 94%) over the concentra-
tion range of 50 ng/mL to 1,000 ng/mL with α1-acid-
glycoprotein (AAG) being the principal binding protein.
One of the original studies regarding the clinical
pharmacology of these agents was reported by Kelly and
O’Connor [78, 83] in their early phase experience with
vorinostat. These studies were initiated with an IV
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formulation, and later employed an oral formulation of
vorinostat. A direct comparison of the toxicity and pharma-
cokinetic profile of IV versus oral vorinostat revealed that the
Cmax of exposure to vorinostat was substantially higher with
the IV formulation vs oral formulation (2,408 ng/ml vs
658 ng/ml) and the area under the curve of exposure (AUC)
was substantially greater with the oral route of exposure
(4,634 hxng/ml vs 101,854 hxng/ml). Interestingly, the
toxicity profile of these two regimens was also markedly
different with more thrombocytopenia, dehydration and
diarrhea with the oral formulation as compared with the IV.
Since this experience, there remains some debate regarding
the optimal pharmacokinetic strategy to employ in adminis-
tering HDAC inhibitors. For example, are these agents more
efficacious with a more Cmax profile of exposure, or is daily
oral dosing optimal. Of course, irrespective of these routes of
administration and discrete PK issues, the half life of the
individual agent will be an important determinant of dose and
schedule.
Extensive pharmacokinetic monitoring in clinical
trials has revealed that, romidepsin undergoes extensive
metabolism in vitro primarily by CYP3A4 with minor
contribution from CYP3A5, CYP1A1, CYP2B6, and
CYP2C19. At therapeutic concentrations, romidepsin did
not competitively inhibit CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP2E1, or CYP3A4 in vitro. Similarly oral
vorinostat is 71% bound to proteins and is metabolized
via glucuronidation and hydrolysis followed by beta-
oxidation into two inactive metabolites. Biotransforma-
tion by cytochrome P450 is negligible. It is renally
excreted with <1% of the dose recovered as unchanged
drug in the urine. The mean urinary excretion of the two
pharmacologically inactive metabolites at steady state
was 52±13.3% of vorinostat dose; 16±5.8% of the dose
Table 2 Classification of histone deacetyalse inhibitors
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as O-glucuronide and 36±8.6% of the dose as 4-anilino-
4-oxobutanoic acid of vorinostat.
In clinical trials histone acetylation seen in mononuclear
cells in the peripheral blood is considered to be a biomarker
for reaching target and the effect and can persist up to 10 h
[78] after the drug has cleared from the system after an oral
dose. Interestingly, as shown by Kelly and O’Connor [78,
83], higher doses of vorinostat did not necessarily produce
more acetylated histone, but generally resulted in a longer
half-life of the acetylated H3/H4. Obviously, whether this
would be true for other protein targets (p52, Bcl-6, etc)
remains to be determined. Despite the role of H3/H4
acetylation, it is important to recognize that accumulation
of acetylated H3/H4 can be demonstrated in every patient
(very similar to the proteasome inhibitor story), and that
accumulation of the Ac-H3/H4 does not correlate with
response. Identifying appropriate surrogate biomarkers of
response with HDAC inhibitors continues to be a major
pursuit.
The side effect profile of all HDAC inhibitors is fairly
uniform across even the diverse chemical classes of agents.
The most common side effects include fatigue, nausea, and
diarrhea [1, 5, 10, 84]. Transient thrombocytopenia is the
most common myelosuppressive effect. During the phase 1
experience with vorinostat, bone marrow examination of
patients at their platelet nadir revealed a normocellular
marrow with somewhat dysplastic appearing megakaryo-
cytes that appeared to have impaired platelet budding [83].
This observation was also seen with LBH689 as well.
Subsequent studies have revealed that HDAC inhibition
may repress GATA-1 gene an important transcription factor
for heamtopoeisis [85], leading to a delay in megakaryocyte
maturation and thrombocytopenia [86].
One of the recurring themes of HDAC inhibitors relates
to the cardiac effects of these agents. Prolongation of the
QTc interval has been observed as a class effect for many
HDAC inhibitors and is thought to occur via the HERGK+
channels [87, 88]. This was first noted in a 15 patient phase
II romidepsin trial that had to be halted due to a fatal
cardiac event and an unexpected incidence of serious
cardiac arrhythmias seen in five patients (two asymptomatic
nonsustained ventricular arrhythmia, three prolonged QTc
interval) [89]. A subsequent systematic study of cardiac
events resulting from treatment with romidepsin (282
administered cycles of Romidepsin and over 700 doses of
the drug), demonstrated that almost all patients had some
prolongation of the QTc interval (median 14 ms) and more
than half the patients had transient EKG changes including
T wave flattening and ST depression [90]. These changes
were clinically insignificant with no change in cardiac
Table 3 Listing of single agent hdacicurrently in clinical trials for lymphoproliferative disorders
Class Agent Isotype selectivity Formulation State of clinical development in lymphoid malignancies
Hydroxamic acid Vorinostat I,2a,2b,4 Oral, IV FDA approved for CTCL
phase II trials for NHl and HD
TSA 1,2,4 Not in clinical use
LAQ824 1,2,4 Phase 1 studies
LBH589 (Panobinostat) 1,2a,2b,4 Oral Phase II studies
Pursuing approval I track in Hodgkin lymphoma
PXD101 (Bellinostat) 1,2a,2b,4 Oral, IV Phase 1 studies in NHL
Phase II studies in PTCL,
Pursuing approval track in PTCL
ITF2357 [132] 1,2,4 Oral Phase II studies in relapsed and refractory
Hodgkin lymphoma-
CRA-024781 1,2b Oral Phase 1 studies
SB 939 Unknown Oral Phase 1 studies
Short chain fatty acids Sodium butyrate 1,2a Not in clinical use
Valproic acid 1,2a Oral Case reports
Combination trials
AN-9 NA Phase II trials
Bezamides SNDX-275 [133] 1,2,3,9 Oral Phase II trials in Hodgkin lymphoma
Etinostat
MGCD0103 1,2,3,11 Oral Phase 1 Expanded to phase II in Hodgkin lymphoma
based on Impressive activityPimelic diphenylamise 1,2,3
Cyclic peptides Romidepsin 1,2,4,6 IV FDA approved for CTCL
Possible approval for PTCL likelyapcidin 1,2
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enzymes or cardiac function. The agent is now approved
with the caution that the treating physician should be
careful in giving the drug to patients who may have a
significant cardiac history or be susceptible to prolongation
of the QTc interval. It is recommended that attention be
paid to maintaining the patient’s potassium and magnesium
levels within the normal range while receiving therapy with
romidepsin. Due to the early experience with romidepsin,
most trials with HDACI now require rigorous cardiac
monitoring. It is also recommended that patients with
baseline prolonged QTc, significant heart disease, or
patients on medications that may prolong the QTc interval
be excluded from trials with HDAC inhibitors. Various
HDAC inhibitors have also been shown to vary in their
cardiac effects. Vorinostat, for example, has not shown to
be associated with any serious cardiac toxicity whereas the
hydroxamic acid panobinostat (LBH589) and its predeces-
sor LAQ824 are associated with QTc interval prolongation
(one patient had tosrdaes de pointes) [91, 92]. Encourag-
ingly, there were no reported long term changes in the EKG
seen in any of the patients treated on trials of HDAC
inhibitors. Thrombosis and pulmonary embolism are other
important adverse events noted on the pivotal vorinostat
trials (two patients experienced thrombosis and pulmonary
embolism) [93]. It was unclear if this was directly related to
the drug, but it is recommended that caution be used while
using vorinostat in patients who may have an underlying
thromboembolic disorder, an increased incidence of throm-
boembolic events has not been reported on the ongoing
clinical trials with HDACI.
Clinical activity of HDAC inhibitors
in lymphoproliferative malignancies
B-cell lymphomas
Lymphomas are the most common hematological malig-
nancy in the United States and constitute about 5.4% of all
cancers with a yearly estimated incidence of 66,000 cases
of NHL and 5,000 cases of HL per year [94]. B-cell NHL
are the most common type of lymphomas and include
subtypes that vary from some of the most aggressive
tumors known to science (Burkitt’s lymphoma) to some of
the most indolent (follicular and small lymphocytic). The
lymphomas are readily classified into aggressive subtypes,
for which urgent chemotherapy is required to affect cure, or
indolent diseases, which are more typically managed as
chronic diseases. As a result, treatment is often tailored to
the aggressiveness of the disease, with dose intense
combination therapy and possibly autologous bone marrow
transplant being considered for aggressive histologies like
with Burkett’s lymphoma, mantle cell lymphoma and diffuse
large B- and T-cell lymphoma, while single agent rituximab
and less dose intense chemotherapies are routinely employed
for the more indolent subtypes of disease.
With this background, the development of new drugs for
the treatment of lymphoma can be viewed as falling into
one of several distinct categories: (1) simple single agent
regimens that have a role in managing relapsed or
refractory diseases (ex: bortezomib, pralatrexate for PTCL,
vorinostat and romidepsin for CTCL, rituximab for indolent
lymphomas); (2) integration of an active agent into an
existing regimen to exploit possible synergistic effects (ex:
rituximab plus CHOP or EPOCH); (3) use of the agent as a
maintenance therapy following definitive chemotherapy
(ex: rituximab, trials of lenalidomide in mantle cell
lymphoma). In this context, each and every one of these
opportunities exists across the many disease sub-types of
NHL. Hence, there is a need to develop novel therapies for
patients with NHL to continue to improve outcomes, which
have clearly improved dramatically over the past decade.
HDAC inhibitors, given their reasonable side effect profile
and compelling effects on molecular pathways that may be
important in lymphomagenesis, clearly have the potential to
impact all these major areas of drug development. Present-
ly, there are no HDACI agents that are approved specifi-
cally for the treatment of B-cell lymphomas, though there is
data with select inhibitors, and a strong rationale remains
intact for their use in B-cell malignancies. Mechanistically
one disease where there appears to be a strong rationale,
though with minimal clinical data to date, is in mantle cell
lymphoma. This unique disease is grossly characterized by
marked dysregulation of cyclin D1 mediated by the t(11:14)
translocation, and loss of the cyclin dependent kinase
inhibitors (cdk) p21 and p27. Interestingly, two of the
prominent effects of HDAC inhibitors is down-regulation
of cyclin D1, and up-regulation of p21/p27. The idea that
one drug could potentially revert these pathognomonic
molecular features represents a promising venue for
thinking about how to rationally employ such agents for
such a challenging disease. Similarly, the association of
dysregulated BCL-6 in many cases of DLBCL and the
effects of HDACI on BCL6 as described in the section
above can potentially provide a rationale for the therapeutic
opportunity.
Perhaps one of the earliest demonstrations of activity of an
HDAC inhibitor in B-cell lymphoma was with one of the
oldest HDAC inhibitors used in medicine, namely valproic
acid (Depakote). Valproic acid, approved for the treatment of
seizure disorders, induced a complete remission in a patient
with multiply relapsed transformed follicular lymphoma, and
was one of the first published reports of the efficacy of HDAC
inhibitor in the treatment of B cell malignancies [95]. Valproic
acid, an acknowledged though weak inhibitor of histone
deacetylases, has been more widely studied in myeloid
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leukemias, with little to no other experiences in lymphoid
malignancies.
Beyond valproic acid, there have been several early
phase trials with a variety of other HDAC inhibitors for the
treatment of B-cell NHL. Kelly and O Connor [78] reported
on the first phase 1 study of intravenously administered
vorinostat (previously known as suberoylanidie hydroxamic
acid, or SAHA) in patients with solid tumors and
hematological malignancies. Of the 11 patients with B-cell
malignancies (HL n=5, NHL n=6 ), no patients with B-cell
NHL responded, though antitumor activity was seen in two
patients with HD including a 30% reduction of tumor
burden in one patient which was maintained for 3 months
and stable disease in another patient for 8 months. A
follow-up Phase 1 study conducted by the same inves-
tigators [83] with an oral formulation of vorinostat revealed
a very favorable side-effect profile, and a maximum
tolerated dose of 400 mg per a day given for 14 consecutive
days on an every 21 day cycle. This study enrolled a total
of 25 patients with hematological malignancies, with the
best response being a complete remission (CR) seen in a
patient with transformed follicular lymphoma. Partial
responses (PRs) were seen in patients with transformed
lymphoma and mycosis fungoides. A patient with Hodg-
kin’s disease had a 31% decrease in disease lasting for
10 months. These two studies of vorinostat in patients with
solid tumor and hematologic malignancies were among the
first to demonstrate the potential activity of these com-
pounds in B-cell malignancies and Hodgkin lymphoma.
Another Phase 1 trial of oral vorinostat has been conducted
in patients with B-cell malignancies, as recently reported by
investigators in Japan. This trial enrolled ten patients with
B cell lymphomas at two dosing levels: 100 mg and
200 mg bid for 14/21 days. Four of the ten patients
responded, including two CRs and one PR seen in patients
with follicular lymphoma (FL) and one PR in a patient with
MCL [96]. A dedicated phase 2 study of vorinostat in
patients with relapsed DLBCL [97] at a dose of 300 mg bid
(14 days per 3 weeks or 3 days per week) has been
reported. Eighteen patients were enrolled, with one patient
obtaining a CR lasting 468 days, and one patient who
attained stable disease for 301 days. Based on this study,
and the collective experience from the Phase 1 studies, it
was concluded that vorinostat did not exhibit impressive
single agent activity in large B-cell lymphoma. However, it
should be noted, that the MTD now part of the label for
vorinostat, was not used to assess response in these studies,
and in fact, based on the phase 1 experience, as well as data
generated by Duvic et al. in CTCL, this particular dose was
found to be poorly tolerated. A second phase II study
evaluated vorinostat at a dose of 200 mg bid for 14/21 days
in patients with relapsed and refractory indolent NHL. This
trial enrolled 33 out of which four patients achieved a CR,
two attained a PR and 4 had stable disease [98]. These
experiences seem to suggest that while the single agent
activity of vorinostat in DLBCL is variable, and probably
low, it raises two question: (1) why do select patients can
achieve CR, while other don’t; and (2) what is the optimal
pharmacokinetic profile.
The experience with vorinostat has prompted further
evaluation of other more potent HDAC inhibitors for the
treatment of lymphomas. Parallel to the development of
these agents in myeloid malignancies, most phase I trials
are conducted to include the broad category of lymphoid
diagnoses that initially encompass both B- and T-cells with
the idea of expanding the trial to a specific subtype if a
positive signal is seen in a specific diagnostic group.
Belinostat, another HDAC inhibitor that belongs to the
class of hydroxamic acids is currently in development for
the treatment of lymphoma, in particular peripheral T-cell
lymphoma (PTCL). Similar to vorinostat, it has an oral and
IV formulation, though the majority of data collected to
date is with the IV formulation. The initial phase I trial of
belinostat in advanced solid tumors established a maximal
tolerated dose (MTD) of 1,000 mg/m2 given IV for 5 days
as a 30 min infusion. This dose was confirmed as the MTD
in a parallel study of the same agent in hematological
malignancies with no additional toxicity seen in this group
of patients. This study enrolled 11 patients (DLBCL n=7,
transformed CLL n=2, transformed FL n=4, CLL n=2).
No objective responses were seen in any patients though
some patients experienced stabilization of disease (DLBCL
n=2, CLL n=3). For ease of administration, the oral
formulation of belinostat is being developed and a Phase
1 study of oral belinostat in patients with all sub-types of
NHL is underway. The starting dose was 750 mg/m2 with
planned escalations until MTD is reached. Interim results
on nine patients were reported at ASCO 2009 [99]. Tumor
shrinkage in the range of 43% to 49% was reported in one
patient with MCL and two patients with Hodgkin lympho-
ma. Accrual continues as MTD has not been reached with
present cohorts being treated at doses well above the MTD
reached with the IV formulation again alluding to the
differing properties of oral and IV forms of these agents.
Another orally administered HDAC inhibitor PCI-2478,
belonging to the class of hydroxamic acid is being
developed for the treatment of lymphomas. Evans et al
have reported the results of the initial phase I data at ASH
2010. One patient with follicular lymphoma achieved a CR
[100] while four PRs and seven SD responses were noted in
20 evaluable patients. This study has shown that there are
no cardiac effects or prolongation of the corrected QT
interval (QTc) interval noted with this agent. A phase II
portion of the trial is planned. Several other HDACI in
development for various lymphoid malignancies are listed
in Table 3.
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While the experience with HDAC inhibitors as single
agents in B-cell lymphoma has been less than hoped for, it
is clear these drugs have important potential activity, and
that the likely path forward will involve rational combina-
tions. In addition, the experience with all the available
HDAC inhibitors is not consistent, as some have minimal to
no data in B-cell malignancies. It will be important to gain
a better understanding of how the various classes of HDAC
inhibitors work in B-cell lymphoma, and to try and develop
some reasonable hypotheses around how these agents are
likely working in these DLBCL. With this experience
intact, the emergence of potentially important HDAC
inhibitor combinations will emerge. As we will discuss
below, understanding the molecular pharmacology in the
context of understanding the molecular pathogenesis also
highlights logical drug: drug combinations likely to be
synergistic in particular disease settings.
Hodgkin lymphoma
Hodgkin’s lymphoma (HL) carries a cure rate of over 85%
with either primary therapy or salvage therapy with high
dose chemotherapy and stem cell transplantation. Patients
who fail these first and second line regimens typically have
a poor prognosis with a median survival of 3 years [101].
While there appear to be many drug emerging for the
treatment of NHL, it has been less obvious how any of
these agents might perform in patients with relapsed or
refractory Hodgkin lymphoma. To date, several HDAC
inhibitors have shown activity in relapsed HL, and after T-
cell lymphoma, it is the one disease venue where the
clinical data is compelling enough to now entice some
sponsors to pursue registration directed studies in HL.
Many lines of in vitro data support the potential activity of
several HDACI against HL cell lines. HL is characterized by a
high level of cytokine secretion from the inflammatory
infiltrate surrounding the pathognomic Reed Sternberg (RS)
cells. These cytokines include, IL-5, 6,7,9,10,13 and thymus
activation-regulated chemokine (TARC/CCL17). These cyto-
kines, many of which are part of an autocrine loop are thought
to function by activating the JAK/STAT pathways, resulting in
continual activation of the STAT family of transcription
proteins. In particular, STAT3 and STAT6 are known to be
frequently activated in HL. STAT3 activation is induced by
several cytokines including IL-2, 6, 7, 9, 10,15 , while STAT6
is induced primarily by IL4 and IL13—and may be dependent
on an autocrine IL-13 loop secreted by Reed Sternberg cells
[102]. Phosphorylated STAT6 localizes to the nucleus and
induces the expression of STAT6 target genes that include
TARC and IL-13 as well as other cytokines that attract
lymphocytes that belong to the Th2 class into the tumor
microenvironment [103–105]. These lymphocytes are in-
volved in humoral immunity and promote allergic responses.
This suggests the importance of STAT 6 in the survival of
Reed Sternberg cells as well as promoting the unique cellular
and immunologic milieu that is a hallmark of HD.
Interestingly, STAT regulation involves phosphorylation as
well as lysine acetylation, which implies that HDAC
inhibitors could play a role in regulating critical features of
the HL biology [106]. This is supported by the following
evidence. Buglio et al [107] have demonstrated that exposure
of HL cells (L-428 and KM-H2) to vorinostat showed an
increase in histone acetylation and p21 expression, and
caspase mediated apoptosis. Vorinostat selectively inhibited
STAT6 phosphorylation and was shown to result in
decreased mRNA levels of STAT6 by PCR and a reduction
of TARC as a downstream effect. Changes in cytokines were
evaluated in the supernatants of exposed cells which
demonstrated an increase in the level of IL13 and IP-10
(interferon inducible protein), and a significant decrease in
the level of IL-5, confirming a shift in the Th1/Th2 cytokine
balance. Another target gene regulated by STAT6 is the
antiapoptotic Bcl-xL, which was shown to be significantly
decreased in the HL cell lines following vorinostat exposure.
This reduced level of Bcl-xl could alone reduce the apoptotic
threshold sufficient enough to allow for rational combina-
tions with other HL active agents. In addition to these effects
on growth and survival pathways, it is also clear that HDAC
inhibitors, either alone or in combination with a hypomethy-
lating agent, can also influence antitumor immune responses
by affecting the expression of proteins like the cancer testis
antigens (CTA), which include MAGE, SSX and NY-ESO,
in a variety of tumors including HL [108]. These immuno-
modulatory effects may also contribute to the therapeutic
activity of these agents in HL.
Clinically, there are now a several studies that seem to
consistently demonstrate that HDAC inhibitors have activ-
ity in Hodgkin’s lymphoma. One of the earliest insights into
this signal was revealed in the phase 1 experience with
vorinostat. In the IV and oral phase 1 experiences with
vorinostat, 12 patients with relapsed or refractory HD were
treated with escalating doses of vorinostat, with four
patients exhibiting responses as follows: On the IV study,
one patient attained a PR that lasted for approximately
9 months, one patient experienced a 14% decrease in her
lung disease resulting in significant improvement of her
performance status, and a third patient achieved a 42%
reduction of the tumor lasting for 2 months. On the oral
study, one patient achieved a 31% decrease in tumor lasting
nearly 10 months A subsequent phase II trial of vorinostat
administered at 200 mg orally given twice a day for 14 of
21 days produced only modest clinical activity, with only
one patient achieving a PR [109]. It should be appreciated
that the phase 1 experience with oral vorinostat established
a MTD of 400 mg given orally once a day 14 of 21
consecutive days. This in fact is the recommended dose and
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schedule in the label of vorinostat for use in patients with
relapsed or refractory CTCL. In fact, as we will see shortly,
a well performed systematic analysis of different doses and
schedules of vorinostat in CTCL clearly reaffirmed this
MTD, and also provided data that alternative doses and
schedules were less likely to produce clinical activity. Most,
if not all phase 2 experiences with vorinostat in NHL,
beyond CTCL of course, have been performed with
alternative doses and schedules of vorinostat, raising an
important issue: phase 2 studies employing schedules other
than 400 mg PO daily may be using suboptimal dosing
schedules, and thus, poor evidence in these phase 2 studies
could reasonably be attributed not merely to the ‘activity’
of vorinostat in that context, but rather, to the dosing
schedule. It will be important in future studies of vorinostat
to employ at least the recommended phase 2 dose and
schedule when exploring activity in different disease
scenarios.
Of the available HDAC inhibitors, panobinostat is being
studied in a registration directed phase 2 trial in Hodgkin
lymphoma. The initial phase IA/II trial of panobinostat
(LBH589) employed 2 different dose levels and schedules
of this agent in patients with hematological malignancies.
Patients with HL were entered onto the study at two dose
levels: Arm 1 was dosed at a starting dose of 30 mg a day
given Monday, Wednesday and Friday (MWF) every week,
while arm 2 was initiated at 45 mg a day given on the same
MWF every other week schedule. There were 13 patients
with HL that were enrolled on the study, of which five met
criteria for a partial response indicating evidence of activity
HL. It appeared to be well tolerated with fatigue, nausea,
thrombocytopenia and diarrhea being the most common
side effects. The MTD was estimated by the logistic
regression model and was defined as 40 mg a day given
every MWF on the weekly schedule [110, 111]. Based on
this data, a large international phase II trial of panobinostat
is designed for patients with relapsed and refractory HL.
While the study is now on going interim results were
reported on 81 patients at ASCO 2010 with responses seen
in 17 patients, two patients attaining a CR and 15 patients
attaining a PR, despite the fact that the study population
appears to be very heavily treated [112, 113].
Another HDAC inhibitor with activity in Hodgkin’s
lymphoma is MGCD0103, which belongs to the benzamide
class. MGCD 0103 is classified as an isotype selective
HDAC inhibitor that predominantly inhibits class 1 HDAC
enzymes and is administered as an oral formulation. A
phase II trial of MGCD0103 was conducted at a dose level
of 110 mg given orally three times per week in patients
with relapsed and refractory HL. Responses were seen in
seven of the 20 patients that were treated at this dose level
including complete remissions; however the dose was
considered too toxic, requiring frequent interruptions and
dose reductions. The protocol was then revised to lower the
dose to 85 mg per day give on the same schedule. Another
ten patients were enrolled on the lower dose and partial
responses were seen in three of the ten patients. The agent
was well tolerated with the main side effects being fatigue
and thrombocytopenia, though two patients developed
pericardial effusions requiring an interruption of the
protocol [114]. Collectively, these data suggest that there
is a signal of efficacy of some of the more potent HDAC
inhibitors in HL but the biological correlates of this activity
are still unclear.
T cell lymphomas
Mature T-cell non-Hodgkin Lymphoma and NK-cell neo-
plasm’s comprise about 12% of all NHL and 15–20% of
aggressive lymphomas worldwide. They are characterized
by great morphological diversity and genetic variation even
within individual disease entities. The current 2008 WHO
classification recognizes over 20 types of mature T-cell and
NK T-cell lymphomas (PTCL) [115]. Cutaneous T cell
lymphomas (CTCL) are malignancies that arise in the skin
and are classified as a separate entity based on their distinct
clinical behavior and prognosis [116]. Among the aggres-
sive lymphomas, a T-cell phenotype confers a worse
clinical outcome compared to their B-cell counterparts,
with the exception of ALK-positive ALCL. Long-term
survival at 5 years remains at 10–30% for most histologies
with present treatment strategies [117] and relapsed and
refractory disease remains a significant clinical dilemma.
For reasons that are not entirely clear, HDAC inhibitors
have shown relatively consistent and promising activity in
the treatment of many types of T-cell lymphoma. In fact,
two agents of this class, vorinostat (Zolinza) and romidep-
sin (Istodax) have been approved for the treatment of
relapsed or refractory CTCL in the US. In addition,
romidepsin, belinostat and panobinostat are all in clinical
trials for T-cell malignancies, including peripheral T-cell
lymphoma.
From a mechanistic perspective, it has been difficult to
assign a precise mode of action of this class of drugs to any
lymphoma, let alone CTCL or PTCL. It is not even clear if
histone acetylation is essential for the biological activity
seen in T-cell lymphomas. Pharmacodynamic studies have
shown that histone acetylation can be demonstrated in
peripheral blood mononuclear cells as well as [83] tumor
tissue from patients with T-cell lymphoma following
treatment with HDAC inhibitors, however, there is no
correlation with clinical response to these agents [83].
Essentially every patient achieves acetylation of histone.
Duvic et al. [118] have attempted to look at biological
correlatives of HDAC inhibitor therapy in patients with
CTCL by performing serial skin biopsies on patients
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receiving vorinostat on trial at 2 h, and then at 4, 8 and
12 weeks after initiation of treatment. These results
established the following: at 4 weeks, 39% of the patient
samples demonstrated lymphocyte depletion consistent
with the anti-lymphoma effect of vorinostat. Samples were
also studied for acetylated histones at baseline and then at
4 weeks post therapy. Increased acetylation within lympho-
cytes post-therapy could not be demonstrated or correlated
with response as most of the lymphocytes were not present
after treatment. At 4 weeks post-therapy, there was a
decrease in dermal microvessel density as measured by
CD31 positivity on dermal vessels in all patients which was
significantly lower in responding patients (p=0.001). Prior
cell line data using the CTCL cell line HH indicated that a
24 h exposure to vorinostat resulted in an 8-fold increase of
the antiangiogenic protein TSP-1 as studied by gene
expression array, Consistent with the cell line data, an
increase in the dermal TSP-1 staining was noted at 2 h in
four out of eight patient samples including two responders,
and at 8 weeks a dermal increase in TSP-1 was demon-
strated in six of the 17 paired lesions including four of the
six responders. Another important protein that is constitu-
tively activated in CTCL is p-STAT3, which can be
detected by immunohistochemical stains either in the
nucleus or cytoplasm within both the keratinocytes and
the lymphocytes present within lesions. In this study,
nuclear staining for p-STAT-3 was prominent in both
keratinocytes and lymphocytes prior to the start of therapy.
After 4 weeks of therapy with vorinostat, the staining
pattern shifted to localization within the cytoplasm in nine
of the 11 patients who responded, where as this shift was
noted in only three of the 16 non-responders. This shift was
noted as early as 2 h after treatment in four of 11 paired
lesions [59].
Using a similar model of paired skin biopsy, Prince et al
performed gene expression profiles (GEP) and real time
quantitative PCR on skin samples from six patients with
cutaneous T cell lymphoma who were being treated with
panobinostat in a phase I trial. These biopsies were obtained at
0, 4, 8 and 24 h after administration of drug. In this study there
were ten patients with a diagnosis of relapsed CTCLwhowere
treated at varying dose levels as part of a large phase I study in
patients with hematological malignancies. One patient re-
ceived drug at 30 mg a day at the MWF weekly schedule and
the remaining nine patients received panobinostat at 20 mg a
day on MWF weekly. Clinical efficacy was observed in eight
patients (two achieved a CR at both dose level and four
patients achieved a PR, two patients had stable disease (SD)).
The skin biopsy data demonstrated that there was hyper-
acetylation of histone H3 observed in tumor cells as early as
4 h after treatment. Consistent with previous data, histone
acetylation within mononuclear cells was demonstrated in
both responders and non-responders up to 48 to 72 h after the
last oral dose indicating that this could not be used as a
therapeutic marker. GEP data from all six patients consistently
showed that panobinostat induced transcriptional regression
of a greater number of genes than activation. Further statistical
analysis indicated that 20 genes were consistently repressed
and three genes were consistently activated following treat-
ment with panobinostat. The genes that were consistently
affected included genes affecting cell cycle (CCNDI, IGFI)
apoptosis (septin10, TEF, SORBBS2), angiogenesis
(GUCY1A1, ANGPT1) and immune modulation (LAIR1).
Interestingly, CDKN1A, which codes for p21, has been
shown to be consistently unregulated in response to HDAC
inhibitor therapy, though in this study upregulation of p21 was
not consistently seen in all patients. Of the 23 genes, 4 were
further selected for validation by QRT-PCR. These data
confirmed downregulation of guanylate cyclase 1A3
(GUCY1A3), the proangiogenic gene ANGPT1a and the
transcription factor COUP-TFII (NR2F20 which is an
upstream regulator of ANGPT1 and CCND1). This affect on
genes controlling angiogenesis is consistent with the effects
noted by Duvic et al. [59] {as discussed above and provides
confirmation that the anti-angiogenic affects of HDAC
inhibitor therapy may be important in their mechanism of
action. Bates et al. [119] have conducted a clinical trial of
romidepsin in patients with PTCL and CTCL and have also
looked at the biological correlates of activity of HDAC
inhibitor therapy. Predetermined markers of HDAC inhibitor
activity including global histone acetylation were studied in
peripheral blood sample. In addition tumor samples were
collected to look for ABCB1 gene (encodes for the p-
glycoprotein MDR) expression and an increase in the level
of fetal hemoglobin as these genes were known to be
modified by HDAC inhibitors therapy. The histone acetyla-
tion data correlated with PK parameters of AUC and C max,
though there was no correlation between response, histone
acetylation and the expression of either ABCB1 or fetal
hemoglobin.
Increasingly, T-cell malignancies are found to be
associated with dysregulation of the T-cell receptor (TCR)
signaling and the immune function which contributes to the
clinical syndrome. Hence, it is likely that the therapeutic
effects of HDACI in T-cell lymphomas may be related to
their effects on TCR and the associated immune effects.
Investigators have started to look at the effects of HDAC
inhibitors particularly vorinostat on TCR signaling and the
immune system in order to delineate a more specific
mechanisms of action for this agent, as well as to
understand the basis for combining it with other agents.
Woznial et al. [120] have performed extensive studies using
GEP on a panel of CTCL cell lines (HH, HUT78, MJ,
Myla, SeAx) that were exposed to vorinostat at various
time points. Their results show that as previously seen
vorinostat exposure resulted in apoptosis in these cell lines
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in a dose dependent manner, affected cell cycle progression
(G2M and G0/G1 arrest) and induced hyperacetylation of
all four core histone proteins. GEP confirmed that 20% of
the genes were significantly activated or repressed in
response to vorinostat in 24 h. The functional analysis of
these altered genes revealed pathways that have already
been identified as being affected by HDAC inhibitors
including cycle regulators for G1/S transition (E2F, E2F4,
CDK4, CDk6, Cyclin A2, D2,D3,E20) ,G2/M regulators
(CDC23, CD25B and CHEK4), apoptosis (FAS, IRAK1,
CASP6, BID, BCL2), antiproliferative genes as well as
multiple mitogen activated signaling kinase (MAPK)
signaling pathway ( MAPK1, MAP3K6, MAP3K14) as
described in the sections above. However, this study has
demonstrated changes in genes that are involved in the
JAK/STAT signaling pathway, cytokine–cytokine interac-
tion and expression of receptors belonging to the tumor
necrosis factor (TNF) family, all important pathways for
survival and differentiation of lymphocytes and the immune
system. Vorinostat treatment was shown to shift the
expression profile of cytokines resulting in increased
expression of interleukins like IL1a, IL6, Il9, and a
decrease in the expression of IL4, IL5, Il10, IL11 and their
associated receptors. Overall the cytokine profile repre-
sented a state that inhibited lymphocyte growth and
proliferation and inhibited the TH2 type immune responses.
This latter aspect of the drug effect is important as CTCL is
a malignancy of activated T cells and is characterized by
dysregulation of the immune system with reversal of the
Th1/Th2 cytokine profile [121]. Vorinostat has also been
shown to affect genes that affect cell migration and
chemotaxis that may affect the skin homing properties of
malignant cells in CTCL. While it is difficult to list all the
genes that were altered, overall there was a decrease in the
expression of certain cytokine genes like CCL1, CCL22,
CXCL10, CCR4 and CCR6 and an increase in others like
CCR2, CCR6. There were also some alteration in the
expression of members of the JAK/STAT pathway them-
selves like STAT6, STAT5A, SOCS2, (decrease) and
STAT1, STAT3, JAK1 (increase).
Another important pathway required for T-cell survival
and proliferation involves the T cell receptor (TCR). TCR
signaling induces activation of many protein tyrosine
kinases resulting in phosphorylation of many downstream
substrates including CD3 chains, TCR epsilon chain, and
the zeta chain associated with ZAP-70 and phospholipase C
[122]. After antigen stimulation, TCR activation leads to
activation of LCK and FYN which results in tyrosine
phosphorylation, after which ZAP-70 tyrosine kinase is
recruited to the TCR where it acts together with LCK to
activate downstream substrates including PKC, and MAPK
as well as the Jun pathway. In addition, it is linked to the
PI3K/AKT pathway which is important for the survival of
T-lymphocytes through an increased expression of BCL-
XL. Treatment with vorinostat induces repression of all
genes associated with TCR related signaling including
ZAP70, CD3DIL4, IL5, Il10, FOXP3 and upregulated
FYN, IFNG and IL12A. The effects on TCR signaling were
significant and were seen across all cell lines and confirmed
by QRT-PCR. A decrease in the phosphorylated forms of
ZAP-70 and AKT after vorinostat treatment was confirmed
by western blots confirming the inhibitory effects of this
agent on TCR signaling. FYN which seems to be
upregulated by vorinostat functions is a SRC family kinase
that phosphorylates several negative regulators of TCR
signaling and ultimately adds to the negative effect of
vorinostat on TCR signaling pathways. These changes were
seen in cell lines and it is possible that there may be
differences in gene expression that may be seen in actual
tissue samples, and variability associated with the various
subtypes of HDACI.
Clinically, there are many HDAC inhibitors that are
being studied for the treatment of T-cell lymphoprolifer-
ative malignancies. While each has its own strengths and
limitations, we will briefly review those HDAC inhibitors
presently in clinical study for T-cell NHL.
Vorinostat (formerly known as suberoylanilide hydroxa-
mic acid—SAHA) was the first HDAC inhibitor approved
for the treatment of cancer. In the US this agent is approved
for the treatment of CTCL in patients who have failed at
least two prior systemic therapies [1]. Based on early
signals of activity and a favorable toxicity profile in
patients with lymphoma in the phase 1 experience, Duvic
et al. [59] conducted a restricted phase I/II study of oral
Vorinostat in patients with CTCL. This Phase 2 experience
enrolled 33 patients with advanced heavily pretreated
CTCL patients. Three different orally administered dosages
and schedules were sequentially evaluated: 400 mg daily;
300 mg twice daily for 3 days followed by 4 days of rest;
and 300 mg twice daily for 14 days with a week of rest
followed by 200 mg twice daily. The overall response rate
(ORR) was 24.4% with eight patients having a partial
remission (PR) including four patients with Sezary syn-
drome. More importantly, 14 of the 33 patients (42%)
reported significant pruritis relief. The median time to
response was 11.9 weeks, and the median duration of
response was 15.1 weeks. The major side effects included
fatigue, thrombocytopenia, and gastrointestinal symptoms
(predominantly diarrhea and nausea). Within the different
cohorts, more thrombocytopenia was noted in the third
cohort where patients received a higher dose of 300 mg bid
for 14 days straight. However, most of the responses were
seen in Groups 1 and 3. Thus, based on the response rate
and toxicity criteria, the 400 mg per day dose was
established as having the best safety profile. This study
affirmed the findings in the original phase 1 experience,
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supporting the 400 mg PO daily dosing of vorinostat, which
was associated with the most favorable side effect profile
and highest response rate of any of the explored schedules.
It is for this reason that conclusions about the efficacy of
vorinostat with other doses and schedules may be mislead-
ing if the phase 2 study was not conducted at the
recommended Phase 2 dose based on the Phase 1
experiences. Based on these data, a registration directed
phase II study using the 400 mg PO dose was initiated by
Olsen et al. [93]. This study included 74 pts with CTCL
who had failed at least two prior systemic therapies.
Disease assessment was done by modified skin weighted
assessment tools (m-SWAT). This study demonstrated an
overall response rate (ORR) of 29.7%, with one patient
achieving CR after 281 days of therapy. Median time to
objective response was 56 days (28–171) though some
patients took up to 6 months to respond and the median
duration of response was not reached in the study though it
was greater than 185 days. Non-progressing patients
continued on the study with 15 patients receiving drug for
over a year and six patients who received it for more than
2 years. The response to vorinostat was not impacted by
their response to last systemic therapy. In addition, another
29 patients had clinical benefit manifested by stable disease
for over 24 weeks. Prurtis relief was seen in 305 of patients
including responders and non-responders again pointing to
the effect of vorinostat on cytokine profiles. These data
supported the approval of vorinostat by the U.S. FDA in
October of 2006, making it the first HDAC inhibitor ever
approved for the treatment of cancer.
Romidepsin (formerly referred to as depsipeptide, FK228)
is cyclic peptide originally isolated from the broth culture of
Chromobacterium violaceum. It was initially studied at the
National Cancer Institute in patients with refractory or
relapsed solid tumors by Bates and Piekarz. Piekarz et al
reported a case of patient with refractory PTCL that
responded to depsipeptide [123]. As the drug began to
demonstrate a consistent signal in patients with T-cell
lymphoma, the study was expanded to separate out patient
with CTCL from those with PTCL, and then further stratified
patients based on the amount of prior therapy they received.
Overall it had a stratification that consisted of seven different
treatment arms with the intention of separating out different
cohorts of patients with T-cell lymphomas based on
histology and prior number of therapies. All patients received
drug as an intravenous infusion at a dose of 14 mg/m2 once
a week in a 23 out of a 4 week cycle. The two major cohorts
were CTCL and PTCL and the data from these two groups
of patients has been analyzed and presented separately.
Piekarz et al reported the results of 71 patients with relapsed
CTCL that were treated with depsipeptide. The overall
response rate was 34% (24/71) with complete responses
observed in four patients. The median duration of response
was 13.7 months. Based on the data generated by the NCI,
the drug was eventually acquired by Gloucester Pharmaceut-
icals, and two registration directed clinical trials were
launched, one in CTCL and one in PTCL. In the preparation
of the New Drug Application to the U.S. FDA, data from the
two studies (NCI plus Gloucester) was pooled and patients
were analyzed using a composite end point to assess
response using skin assessment, lymph node and visceral
involvement and abnormal circulating Sezary cells. One-
hundred thirty five patients were evaluable with a median
age of 57 years who had received a median of at least 2 (1–
8) prior systemic therapies. One hundred three patients
(76%) had at least stage IIB or higher disease and 19 patients
had SS. The overall response rate (ORR) was 41% with a
complete response (CR) rate of 7% and duration of response
of 14.9 months. Interestingly, the response rate (RR) was
58% in patients with Sezary Syndrome. Unique to the
romidepsin study was a specific symptom assessment tool to
quantify changes in pruritis. In this study a relief of pruritis
was seen in over 60% of the patients. This agent was
approved by the FDA for the treatment of relapsed CTCL
following failure of one line of systemic therapy. This trial
included cohorts of patients with PTCL who had failed at
least one prior systemic therapy. The NCI sponsored study
with 48 evaluable patients showed an overall response rate of
31% with 4 (8%) CRs. Patients who got more than 2 cycles
of therapy had a response rate of 44%. Median Duration of
response was 9 months with a median time to progression of
12 months. The results of the Gloucester sponsored study of
romidepsin in patients with PTCL are still awaited.
Belinostat is a hydroxamic acid with pan HDACI
activity that is currently in clinical trials for solid tumors
and hematological malignancies available in both oral and
intravenous formulation. A Phase I trial of the intravenous
formulation was carried out in parallel to the solid tumor
phase and an MTD of 1,000 mg/m2 was established. This
formulation is being studied in a large phase II trial at a
dose of 1,000 mg/m2 for patients with relapsed PTCL. At
the same time the oral formulation has been developed and
similar to the story with vorinostat has been shown to be
better tolerated than the IV formulation. In the ongoing
phase I trial of belinostat in hematological malignancies,
the dose is up to 2,000 mg/m2 and an MTD is not reached
[124].
Oral Panobinostat, also known as LBH589, is a pan
HDAC inhibitor belonging to the hydroxamic acid group
that has shown remarkable activity in patients with CTCL
in a phase I/II trial. Six out of ten patients with CTCL
showed a response in the original phase 1 trial at a dose of
20 mg and 30 mg MWF on a weekly basis. The trial has
now been expanded to a dedicated phase II in patients with
CTCL at a dose of 20 mg a day MWF given weekly. The
results of this trial are awaited.
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Combinations of HDAC inhibitors with other agents
As noted above, there is ample evidence for the single
agent activity of HDAC inhibitors as anti lymphoma
agents. By targeting specific molecular pathways they also
lend themselves to endless combinations with other targeted
therapies. Some of the more promising combinations and
the mechanistic rationale behind them is discussed below.
Combinations with proteasome inhibitors (PI) Proteosome
inhibitors (PI) act by targeting the catalytic 20S core of the
proteaosome and induce apoptosis in cancer cells by several
mechanisms. They have emerged as a new class of therapeutic
agents that are effective in the treatment of several malignan-
cies including MCL, and T cell lymphomas. Combinations of
HDAC inhibitors and the PI bortezomib show marked
synergistic clinical activity in some lymphoproliferative
disorders like multiple myeloma and mantle cell lymphoma.
Paoluzzi et al. [125] have demonstrated synergistic cytotox-
icty of either belinostat or romidepsin in combination with
boretezomib against a panel of MCL cell lines. The
combination of HDAC inhibitors and PI was shown to
induce mitochondrial membrane depolarization and apopto-
sis in treated cells. A decrease in Cyclin D and BcL-xL was
also demonstrated. The combination of vorinostat and
bortezomib has been evaluated in vitro for synergy against
CTCL cell lines as well. This combination has demonstrated
an upregulation of p21 and p27, an increased expression of
phosphorylated p38, which participates in signaling cascade-
controlling cellular responses to cytokines and stress.
Decreased expression of the VEGF was also demonstrated
after treatment with vorinostat and bortezomib. Combina-
tions of vorinostat and boretezomib were also synergistic in
MCL cell lines resulting in apoptosis, ROS generation, and
decreased NK-kB activity [126]. Similar synergy between
romidepsin and belinostat with boretezomib has also been
reported in CLL cell lines and has been shown to involve
mechanisms of NF-Kappa B inactivation, and perturbation of
the apoptotic pathways [127]. The novel PI carfilzomab is
also being evaluated in combinations with HDAC inhibitors
and has shown promising synergistic activity with vorinostat
[128] in DLBCL cell line. This was associated with
activation of JNK, p38 MAPK, and decrease in NK-kB,
AKT inactivation and Ku70 acetylation. Unexpected synergy
was also noted between the antihistamine cyproheptidine and
boretezomib in MCL cell lines. Cyproheptidine is shown to
be an HDAC inhibitor that resulted in and decreased Cyclin
D expression—a hallmark of MCL. When combined with
boretezomib , the combination was markedly synergistic in
terms of cytotoxicity and was shown to result in apoptosis of
cells [129]. Clinical trials are now underway to evaluate the
combination of proteosome inhibitors and HDAC inhibitors
for the treatment of lymphomas.
Combinations targeting the BCL-6—p53 pathway Bcl6 is
over-expressed in several B cell malignancies particularly
DLBCL and other germinal cell tumors due to mutations of
its genomic locus [50]. In the deacetylated state, Bcl6
functions as a transcriptional co-repressor of several genes
that influence cell cycling and the tumor suppressor p53
activity. Sirtuin2- alpha, a class III HDAC, has been shown
to interact and attenuate p53 mediated function [57]. While,
the BCL-6 can be acetylated and activated by HDAC
inhibitors, nicotinamide (vitamin B3) functions as an
inhibitor of NAD-dependent deacetylation and enhances
p53 acetylation and activation. Recent studies in DLBCL
transcriptional signatures have revealed a subset of
DLBCLs that are particularly dependent on BCL6 to
maintain their survival and these patients could be
candidates for clinical trials of BCL6 inhibitors. The use
of HDAC inhibitors to acetylate and enhance the function
of BCL-6 could conceivably provide a therapeutic target for
antilymphoma therapy. This can be further enhanced by
combining this with an agent like Nicotinamide that can
enhance p53 function to target BCL-6 addicted tumors.
Clinical trials are underway to study this combination.
Other combinations By lowering the apoptotic threshold,
HDAC inhibitors lend themselves as ideal agents to be
combined with chemotherapeutic agents, a strategy that is
being explored in solid tumors and other malignancies andwill
likely be explored in lymphoproliferative disorders. A phase I
clinical trial in patients with advanced CTCL consists of
vorinostat and escalating doses of baxarotene given daily for
28 days. At the time of reporting, 19 patients had been enrolled
and accrual was ongoing as MTD had not been reached.
Responses have been reported in some patients [130].
Another promising platform consists of combining Bcl-2
antagonists ABT-737 with an HDAC inhibitor that has been
studied in various human myeloma and leukemia cell lines
[131]. Vorinostat has been shown to increase the expression
of Bim, Puma and Noxa that was largely sequestered by
bcl-2 and bcl-xl. ABT-737 abrogated this interaction, thus
promoting Bax/Bak activation and apoptosis. Clinical
activity needs to be established in a clinical trial.
Conclusions
The use of HDAC inhibitors has allowed pharmacologic
manipulation of dysregulated genes in cancer cells and have
shown single agent activity against T cell lymphomas,
CTCL, mantle cell lymphomas and HL. The bigger promise
lies in the impact that these agents can have in enhancing
the activity of other targeted therapies ranging from
antifolates like pralatrexate to demethylating agents, pro-
teosome inhibitors, anti Bcl-2 agents. By modifying the
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expression of specific genes and proteins like CD30, or
growth receptors like EGFR it is possible that HDAC
inhibitors could enhance the activity of targeted antibody
therapies like SGN-35 or herceptin. In addition, the vast
effects of HDAC inhibitors on the immune system and
cytokines as seen in CTCL and HL also indicate that
HDAC inhibitors can be useful in the treatment of immune
dysfunction underlying autoimmune disorders, graft vs host
disease. There is also an effort to determine if class
specificity of HDAC inhibitors has a biological significance
and as we get more information about epigenetic dysregu-
lation in lymphoid diseases the clinical significance of this
will become clear. It is likely that in the future an HDAC
inhibitor based therapy will be the backbone of both
upfront and salvage therapies for most lymphomas and
will lead to better outcomes as compared to current
cytotoxic therapies.
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